We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+31.78%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$232M
AUM Growth
+$30.7M
Cap. Flow
-$28.5M
Cap. Flow %
-12.3%
Top 10 Hldgs %
46.06%
Holding
89
New
6
Increased
22
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
WVE icon
Wave Life Sciences
WVE
+$5.79M
2
SAGE
Sage Therapeutics
SAGE
+$2.82M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$2.27M
4
MRSN
Mersana Therapeutics
MRSN
+$2.03M
5
BPMC
Blueprint Medicines
BPMC
+$2M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$25.4M
2
NXTM
NxStage Medical Inc.
NXTM
+$8.93M
3
ASND icon
Ascendis Pharma A/S
ASND
+$2.88M
4
ARGX icon
argenx
ARGX
+$2.66M
5
KURA icon
Kura Oncology
KURA
+$1.73M

Sector Composition

Rank Sector Weight
1 Healthcare 88.92%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
76
Incyte
INCY
$24.4B
– –
-21,500
Closed -$1.37M
CYPH
77
Cypherpunk Technologies Inc
CYPH
$73M
– –
-17,000
Closed -$340K
KA
78
DELISTED
Kineta, Inc. Common Stock
KA
– –
-390
Closed -$177K
APTX
79
DELISTED
Aptinyx Inc. Common Stock
APTX
– –
-14,500
Closed -$240K
CNCE
80
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-105,656
Closed -$1.33M
TBIO
81
DELISTED
Translate Bio, Inc. Common Stock
TBIO
– –
-228,939
Closed -$1.72M
NEOS
82
DELISTED
Neos Therapeutics, Inc
NEOS
– –
-27,500
Closed -$45K
VLRX
83
DELISTED
VALERITAS HOLDINGS INC
VLRX
– –
-66,250
Closed -$431K
NXTM
84
DELISTED
NxStage Medical Inc.
NXTM
– –
-312,119
Closed -$8.93M
LOXO
85
DELISTED
Loxo Oncology, Inc
LOXO
– –
-181,675
Closed -$25.4M
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return

DAFNA Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, DAFNA Capital Management held 89 positions worth $232M, up 15% from $201M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

DAFNA Capital Management withdrew a net $28.5M in Q1 2019, closing 10 positions and reducing 19 holdings. Its most notable exit was Loxo Oncology, Inc, an estimated $25.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 89% a quarter earlier, followed by Financials.

Against the trend, DAFNA Capital Management opened a new position in Mersana Therapeutics worth $2.12M.

  • DAFNA Capital Management's largest Q1 2019 buy was Mersana Therapeutics: 16,132 shares worth $2.12M.
  • DAFNA Capital Management added most to Wave Life Sciences in Q1 2019, an estimated $5.79M increase.
  • DAFNA Capital Management's biggest Q1 2019 reduction was Ascendis Pharma A/S, cutting an estimated $2.88M.
  • DAFNA Capital Management fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $25.4M.
  • DAFNA Capital Management's ten largest holdings make up 46% of its $232M portfolio in Q1 2019.
  • DAFNA Capital Management opened 6 new positions and closed 10 in Q1 2019.
  • DAFNA Capital Management's portfolio value rose 15% quarter-over-quarter to $232M.

Based on DAFNA Capital Management's 13F filing for Q1 2019, filed 15 May 2019.